kwic
low
low
right
on
off
1
1
100
500
strict
ELIZA cgi-bash version rev. 1.91
- Medical English LInking keywords finder for the PubMed Zipped Archive (ELIZA) -
return
kwic search for low out of >500 occurrences
318584 occurrences (No.68 in the rank) during 5 years in the PubMed. [no cache] 500 found
[frequency of next (right) word to low]
318584 occurrences (No.68 in the rank) during 5 years in the PubMed. [no cache] 500 found
| 1) Strategy is still a distant goal for many Low- and Middle-Income Countries (LMICs). |
| 2) lung, vasculature, and intestine is very low and amounted to <1% of liver. |
| 3) ecreases in lipid peroxidation after both low and high dose strawberry phases when c |
| 4) butions to human clearance are relatively low and insignificant when compared with t |
| 5) hepatic clearance of drug compounds with low and intermediate clearance. |
| 6) health appears to be currently limited in low and low-middle income countries. |
| 7) In a low and middle income countries context, t |
| 8) dies on children under 5 years of age in low and middle income countries. |
| 9) d health outcomes of children with SFI in low and middle income countries. |
| 10) healthcare workers (HCWs) particularly in low and middle-income countries (LMICs). |
| 11) However, many women in low and middle-income countries, including |
| 12) worldwide public health problem affecting low and middle-income countries. |
| 13) compartment and the presence of activated low and normal density mature and immature |
| 14) The reported number of adverse events was low, and most studies reported that the av |
| 15) 12.2 Gy) and 6.3 Gy (2.1-11.6 Gy) for the low- and high-dose groups, respectively. |
| 16) four levels of decontamination: cleaning, low- and high-level disinfection, as well |
| 17) findings have implications for studies in low- and lower-middle-income economies whe |
| 18) However, in many low- and middle- income countries (LMICs), |
| 19) ia, and other stakeholders, especially in low- and middle- income countries. |
| 20) With expansion of MPDSR across low- and middle-income countries (LMIC), w |
| 21) re hampered by data gaps, particularly in low- and middle-income countries (LMICs) a |
| 22) ferences between CHW-led interventions in low- and middle-income countries (LMICs) a |
| 23) Health agendas for low- and middle-income countries (LMICs) s |
| 24) olicy on access to medicines in in non-EU low- and middle-income countries (LMICs), |
| 25) cant proportion of intracranial masses in low- and middle-income countries (LMICs), |
| 26) es of ownership increase, particularly in low- and middle-income countries (LMICs). |
| 27) roportionately impacts patients living in low- and middle-income countries (LMICs). |
| 28) proportion of existing studies focused on low- and middle-income countries (LMICs). |
| 29) l settlements (as defined by UN-Habitat), low- and middle-income countries (as defin |
| 30) However, the evidence from low- and middle-income countries and devel |
| 31) Many low- and middle-income countries are adopt |
| 32) e shown that analyses of policy change in low- and middle-income countries are under |
| 33) rbated, with marginalized populations and low- and middle-income countries burdened |
[
right
kwic]
(1)63  and |
(17)5 to |
(33)3 temperature |
(49)2 frequency |
| (2)10 in |
(18)4 SES |
(34)2 ATZ |
(50)2 gestational |
| (3)9 or |
(19)4 concentrations |
(35)2 CT |
(51)2 incidence |
| (4)8 income |
(20)4 quality, |
(36)2 RT |
(52)2 magnification |
| (5)8 socioeconomic |
(21)3 FSS |
(37)2 as |
(53)2 molecular |
| (6)7 birth |
(22)3 SEP |
(38)2 at |
(54)2 oral |
| (7)6 *null* | (23)3 abundance |
(39)2 awareness |
(55)2 protein |
| (8)6 levels |
(24)3 affinity |
(40)2 birthweight |
(56)2 rate |
| (9)6 lipoprotein |
(25)3 back |
(41)2 compound |
(57)2 rates |
| (10)6 patients |
(26)3 compounds |
(42)2 cost, |
(58)2 signal-to-noise |
| (11)5 countries |
(27)3 cost |
(43)2 density |
(59)2 training |
| (12)5 dose |
(28)3 educational |
(44)2 diet |
(60)2 use |
| (13)5 doses |
(29)3 individuals |
(45)2 disease |
(61)2 utilization |
| (14)5 middle-income |
(30)3 inflammation |
(46)2 dose: |
(62)2 variants |
| (15)5 quality |
(31)3 level |
(47)2 evidence |
|
| (16)5 risk |
(32)3 medium- |
(48)2 exposure |
add keyword
--- WordNet output for low ---